MedpaceMEDP
About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Employees: 6,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 55
8.11% more ownership
Funds ownership: 83.04% [Q1] → 91.15% (+8.11%) [Q2]
7% more capital invested
Capital invested by funds: $7.7B [Q1] → $8.22B (+$515M) [Q2]
10% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $11M
1% more funds holding
Funds holding: 578 [Q1] → 583 (+5) [Q2]
4% less repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 224
14% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
UBS Dan Leonard | 35%downside $305 | Sell Downgraded | 29 Jul 2025 |
Mizuho Ann Hynes | 9%upside $510 | Outperform Maintained | 25 Jul 2025 |
Truist Securities Jailendra Singh | 7%downside $436 | Hold Maintained | 23 Jul 2025 |
Deutsche Bank Justin Bowers | 8%downside $430 | Hold Maintained | 23 Jul 2025 |
Barclays Luke Sergott | 4%downside $450 | Equal-Weight Maintained | 23 Jul 2025 |
Financial journalist opinion
Based on 7 articles about MEDP published over the past 30 days
